) is a selective cyclin-dependent kinase (CDK) inhibitor. In this study, we evaluated its effects on primary acute myeloid leukemia (AML) samples (n ¼ 87). In vitro exposure to SNS-032 for 48 h resulted in a mean LD 50 of 139±203 nM; Cytarabine (Ara-C) was more than 35 times less potent in the same cohort. SNS-032-induced a dose-dependent increase in annexin V staining and caspase-3 activation. At the molecular level, SNS-032 induced a marked dephosphorylation of serine 2 and 5 of RNA polymerase (RNA Pol) II and inhibited the expression of CDK2 and CDK9 and dephosphorylated CDK7. Furthermore, the combination of SNS-032 and Ara-C showed remarkable synergy that was associated with reduced mRNA levels of the antiapoptotic genes XIAP, BCL2 and MCL1.
Introduction
The treatment of acute myeloid leukemia (AML) remains unsatisfactory and new therapeutic agents are needed. Recent developments have included the development of targeted therapies designed to exploit the molecular abnormalities that frequently occur in certain AML disease subclasses. Furthermore, these targeted therapies can be used in combination with existing therapies with the intention of achieving longer remission periods. However, to date targeted therapies, including FLT3, 1,2 VEGF 3,4 and aurora kinase 5 inhibitors, have not delivered a survival advantage in this condition.
The cyclin-dependent kinases (CDKs) are a family of highly related serine/threonine kinases that require binding to cyclin partners to become active heterodimeric complexes composed of a catalytic subunit coupled to a regulatory subunit. 6 Some CDKs (CDK2, 4, 6) have a role in cell-cycle regulation by regulating the transition between G1/S phase, S-phase progression and G2/M transition. 7, 8 In combination with extracellular signals and checkpoint pathways CDKs enforce tight regulation of the cell cycle. 9 Deregulated progression through the cell cycle is a hallmark of malignant transformation.
8,10-12 CDK7 complexes with cyclin H and is involved in cell-cycle regulation as the catalytic subunit of CDK activating kinase, which activates CDKs 1, 2, 4 and 6 by phosphorylation and is essential for mitosis. 8, [13] [14] [15] Transcriptional CDKs, including CDK7 and 9, promote the initiation and elongation of nascent RNA transcripts. 7, 10 In addition to its role in the cell cycle, CDK7 is an integral part of transcription factor II H (TFIIH) transcription factor, which phosphorylates serine 5 in the carboxy terminal domain of RNA polymerase II (RNA Pol II) to facilitate transcription initiation. 16 CDK9, as part of elongation factor P-TEFb, phosphorylates serine 2 in RNA Pol II, which is required for elongation. 16 Expression of the CDKs is relatively stable throughout the cell cycle in normal cells, although the cyclins that they are paired with fluctuate over the cell cycle. 12 Expression of CDKs is often perturbed in malignancy making them rational targets for therapy. 17 The aim of drugs targeting CDKs is to inhibit cell proliferation, 9 but some of these new agents have also been shown to be potent inducers of apoptosis in cancer cells. 12 New CDK inhibitors, including SNS-032, are more selective and less cytotoxic 17, 18 and have been shown to prolong stable disease in solid tumors. 7 In this study, we investigated the in vitro effects of SNS-032 in primary AML blasts and AML cell lines both as a single agent and in combination with cytarabine (Ara-C). We demonstrated singleagent activity for SNS-032 and a remarkable degree of synergy with Ara-C in primary cells. Furthermore, we elucidated a putative mechanism of function for SNS-032 that could potentially explain the cytotoxic synergy seen with Ara-C.
Materials and methods

Cell culture
Bone marrow samples were collected in ethylenediaminetetraacetic acid from newly diagnosed, previously untreated, AML patients with the patients' informed consent. In some instances peripheral blood samples were collected instead of bone marrow. Patient characteristics are shown in Table 1 . AML blasts were enriched by density gradient centrifugation using Histopaque (Sigma, Poole, UK) and were subsequently maintained in Roswell Park Memorial Institute medium (RPMI) supplemented with 10% fetal bovine serum. All cultures were maintained at 37 1C in a 5% CO 2 humidified atmosphere. Cell viability was measured on a Vi-Cell XR (Beckman Coulter, High Wycombe, UK) and cell numbers in each culture were monitored by cell counts using the same machine. AML cell lines (HL-60, NB4) were maintained between 2 Â 10 5 and 1 Â 10 6 cells/ml using the culture media described above.
Cytotoxicity assays
In vitro toxicity assays were performed on primary material from 87 AML patients over a 48-h period using a (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) cell proliferation assay (Promega UK Ltd, Southampton, UK). Only samples with a viability of 490% at the start of the assay were included in the analysis. LD 50 values (the concentration of drug required to kill 50% of the cells) were calculated from the sigmoidal dose-response curves. Cells (1 Â 10 5 /well) were treated with SNS-032 (33-4200 nM) and Ara-C (63-8000 nM) by serial dilution and incubated for 48 h in a final volume of 90 ml. Following the culture period, 20 ml of MTS reagent was added and incubated for a further 4 h. The absorbance of the reaction after this time was read by spectrophotometry at 490 nm and the percentage of viable cells calculated relative to untreated control cells in the same assay. LD 50 values were calculated using Calcusyn software (Biosoft, Cambridge, UK).
Annexin V positivity
Cells were treated with SNS-032 at concentrations between 33 and 526 nM, and incubated for 48 h. Annexin V positivity was using the Annexin V Apoptosis Detection Kit (Axxora (UK) Ltd., Nottingham, UK) according to the manufacturer's instructions. Briefly, cells were washed in phosphate-buffered saline (PBS) and resuspended in the supplied binding buffer containing calcium chloride and incubated with fluorescein-labeled Annexin V in the dark for 10 min. Untreated samples were also prepared. Cells were rewashed with PBS and resuspended in binding buffer with 1 mg/ml propidium iodide (PI). Data on the annexin V and PI positivity and forward and side scatter of the cells was collected on a FACS Calibur flow cytometer (Becton Dickinson, Oxford, UK) and analysed using WinMDI software (http://www.methods.info/software/flow/winmdi.html). LD 50 values were calculated using Calcusyn software (Biosoft). All experiments were performed in triplicate.
Caspase-3 activation
AML cell lines were incubated in the presence of SNS-032 at 66, 132, 263 and 526 nM for 48 h. Cells were harvested by centrifugation and washed in PBS and incubated for 1 h at 37 1C in the presence of PhiPhiLux G 1 D 2 substrate (Calbiochem, Nottingham, UK). The substrate contains two fluorophores separated by a quenching linker sequence that was cleaved by active caspase-3. Once cleaved, the resulting products fluoresced green and were quantified using a FACS Calibur flow cytometer.
Cell cycle
Following 24 h of treatment with SNS-032 (33, 66 and 132 nM), 1 Â 10 6 AML cell lines NB4 and HL-60 were harvested in 200 ml of cold PBS, resuspended in 1 ml of ice-cold 70% ethanol and stored at À20 1C. Before analysis by flow cytometry, the stored cells were pelleted and resuspended in 40 mg/ml of PI and 100 mg/ml of RNase (DNase-free) in PBS and incubated at 37 1C for 30 min. Each cell line was tested in triplicate.
Immunoblotting
AML cell lines treated with 0, 131, 263 and 526 nM SNS-032 for 6 h were washed three times in ice-cold PBS, then lyzed by resuspension in lysis buffer (20 mM Tris (pH 7.4), 150 mM NaCl, 1% Igepal (Sigma Aldrich, Poole, UK), 10% glycerol, 10 mM ethylenediaminetetraacetic acid, 20 mM NaF and 3 mM NaVO 4 ) plus complete protease inhibitors (MiniComplete ethylenediaminetetraacetic acid-free; Roche, Burgess Hill, UK) for 30 min at 4 1C followed by centrifugation at 16 000 Â g. The clarified protein lyzates were quantified and equal aliquots were subjected to electrophoresis using NuPage precast 4-12% Bis-Tris gels (Invitrogen, Paisley, UK) followed by transfer to nitrocellulose membranes (Invitrogen). Immunoblotting was performed with antibodies to CDK2, CDK7, CDK9, phospho-CDK2, phospho-CDK7 (Abcam, Cambridge, UK), phopsho-CDK9 (Cell Signaling Technology Inc., New England Biolabs, Hitchin, UK), tubulin (Abcam) and RNA pol II carboxy terminal domain phospho-serine 2 and phospho-serine 5 (Active Motif, Rixensart, Belgium). Blots were visualized by chemiluminescence (ECL Advance; Amersham Biosciences, Piscataway, NJ, USA), with the resultant images being analyzed using a LAS-3000 dark box (Fujifilm UK Ltd, Bedford, UK). The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML E Walsby et al
Quantitative PCR
AML cell lines NB4 and HL-60 treated for 6 h with 131, 263 and 526 nM SNS-032 were harvested for RNA extraction. Untreated cells and cells treated with Ara-C (250, 500, 1000 nM) and SNS-032 and Ara-C in combination (ratio 1:1.9) were collected. RNA was extracted using the RNeasy kit (Qiagen, Crawley, UK) including the on column DNase I treatment according to the manufacturers protocol. A measure of 1 mg RNA was reverse transcribed into complementary DNA in reactions in 5 mM MgCl 2 , 1mM dGTP, 1 mM dATP, 1 mM dTTP, 1 mM dCTP, 1 U/ml RNase inhibitor, 2.5 U/ml MuLV reverse transcriptase, 2.5 mM random hexamers and 1 Â PCR buffer II (ABI). The reaction conditions for the reverse transcription were 25 1C for 10 min, 42 1C for 30 min and 95 1C for 5 min. Quantitative PCR was performed using a Light Cycler and FastStart DNA Master SYBR Green I (Roche) according to the manufacturer's instruction using 1 ml complementary DNA per reaction and specific primers for CDK2, CDK7, CDK9, XIAP, MCL1 and BCL2 The expression levels were compared with ABL expression in the same sample performed concurrently. The primer sequences used were:
Synergy determination with Ara-C Synergy between SNS-032 and Ara-C was assessed in primary AML samples (n ¼ 25) using an experimentally determined constant molar ratio of SNS-032 and Ara-C (1:1.9). To establish the most effective concentration range for each agent, doseresponse curves were generated and LD 50 values were calculated using non-linear regression analysis. In subsequent experiments, cells were treated with serial dilutions of each drug individually and with both drugs simultaneously in a fixed molar ratio. Calcusyn software was used to determine whether any synergy existed between the agents using the Chou and Talalay method. 19 It should be noted that the determination of the optimal molar ratio was constrained by the fact that we only considered clinically relevant doses of Ara-C in these experiments.
Results
SNS-032 is cytotoxic in myeloid cell lines and primary AML samples
The cytotoxic effects of SNS-032 and Ara-C were assessed in primary mononuclear cells isolated from AML patients at diagnosis (n ¼ 87) using an MTS assay. Patient characteristics are shown in Table 1 . SNS-032 induced a mean LD 50 of 139 ± 203 nM following 48 h exposure (Figure 1a) . By comparison, Ara-C was more than 35 times less potent in the same cohort (mean LD 50 ¼ 4.9 ± 5.0 mM). Myeloid cell lines NB4 and HL-60 had LD 50 values of 191 and 153 nM, respectively, when tested under the same conditions. There was only a weak correlation between the sensitivity to SNS-032 and Ara-C in the primary AML samples (r 2 ¼ 0.1532; Figure 1b) . Furthermore, there was no significant difference between the response to SNS-032 and FAB group (P ¼ 0.27), age (P ¼ 0.50) or previous treatment (P ¼ 0.80), sex (P ¼ 0.12), FLT3 mutation status (ITD P ¼ 0.27, TKD P ¼ 0.41) or NPM1 status (P ¼ 0.85). In vitro response to SNS-032 did not correlate with white blood count (WBC) at diagnosis (r 2 ¼ 0.0001, Table 1 ). 
SNS-032 induces apoptosis in both primary AML cells and myeloid cell lines
In this study, apoptosis was measured by annexin V and propidium iodide labeling and was shown to increase in a dosedependent manner in both primary AML cells and the myeloid cell lines NB4 and HL-60 following exposure to SNS-032 for 48 h (Figures 1c and d respectively) . Over the same timeframe, caspase-3 activation was significantly increased when compared with untreated cell populations (Figure 1e ; Po0.05).
SNS-032 results in cell-cycle arrest
Cell-cycle analysis was performed on NB4 and HL-60 cells treated with SNS-032 for 24 h (Figure 2 ). NB4 cells showed increased percentages of cells in the G1 and S phases of the cell cycle while HL-60 cells showed significant accumulations of cells in G1 phase only. When tested by ANOVA the changes in cell-cycle distribution were significant in both cell lines (NB4, P ¼ 0.026; HL-60, P ¼ 0.0002) suggesting that SNS-032 induces a cell-cycle arrest before the induction of apoptosis in these cell lines. It was impossible to assess the cell-cycle effects of SNS-032 on primary AML blasts, as all the ex vivo samples tested showed greater than 90% of the cells in G0/G1.
SNS-032 inhibits the expression of CDK2, and 9 and dephosphorylates CDK7
The protein levels of CDK2, 7 and 9 were determined by immunoblotting at time 0 and after 6 h of treatment of NB4 and HL-60 cell lines with SNS-032. This timepoint was chosen to assess whether changes in CDK expression and/or activation preceded apoptosis induction in the cell lines. Levels of both CDK2 and CDK9 were decreased following exposure to SNS-032 relative to the expression of the a-tubulin loading control (Figures 3a and c) . In contrast, CDK7 expression was not altered by treatment of the myeloid cell lines with SNS-032 relative to the expression of a-tubulin (Figure 3b) . Additionally, the levels of phosphorylated CDK2, 7 and 9 were determined at time 0 and after 6 h of treatment with SNS-032. Phosphorylated CDK7 and CDK9 levels were reduced with increasing doses of SNS-032, whereas there was no change in the levels of phosphorylated CDK2. The transcription of CDK2, 7 and 9 in NB4 and HL-60 cell lines was also assessed following treatment with SNS-032 for 6 h using quantitative PCR. In keeping with the protein data, CDK2 and CDK9 mRNA expression levels were significantly reduced relative to the housekeeping control gene ABL following exposure to SNS-032 (P ¼ 0.022 and P ¼ 0.015, respectively). In contrast, mRNA expression of CDK7 was not significantly altered (P ¼ 0.94), confirming the post-translational effects of SNS-032 on this target protein (Figure 3d ).
The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML E Walsby et al SNS-032 dephosphorylates serine 2 and serine 5 of RNA polymerase II RNA pol II is phosphorylated at serine 5 by the transcription factor TFIIH and at serine 2 integral to P-TEFb. 16 These two phosphorylation events are dependent on CDK7 and CDK9, respectively so we assessed the phosphorylation status of these serine residues following exposure to SNS-032. Primary AML cells, as well as NB4 and HL-60 cells were treated with SNS-032 The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML E Walsby et al for 6 h and the level of phosphorylation of RNA pol II at the serine 2 and 5 residues was measured by immunoblotting and compared with untreated controls. In NB4 and HL-60 cell lines serine 2 phosphorylation of RNA pol II was completely inhibited by SNS-032 at all the concentrations used ( Figure 4a ) while serine 5 phosphorylation was decreased in a dosedependent manner (Figure 4b ). Importantly, we also demonstrated dephosphorylation of RNA pol II at the serine 2 and 5 in primary AML cells (Figure 4c ). The inhibition of serine 2 phosphorylation of RNA pol II suggests that SNS-032 effects elongation of transcription of nascent RNA species through the downregulation of CDK9 expression. The decrease in RNA pol II serine 5 phosphorylation also indicates that SNS-032 affects the function of TFIIH through the dephosphorylation of CDK7. These results are in agreement with a previously published report that showed decreased phosphorylation of serine 2 and serine 5 of RNA pol II after 6 h of treatment with SNS-032 in primary CLL cells.
16 Figure 3 Immunoblotting was performed on protein extracted from NB4 and HL-60 cells treated with SNS-032 for 6 h. (a) The levels of CDK2, (b) CDK7 and (c) CDK9 expressed in the cells were detected, as well the levels of phopshorylated CDK2, 7 and 9. Expression of a-tubulin was used as a loading control. The expression of CDK2 and 9 decreased with increasing SNS-032 concentration, whereas CDK7 expression was not affected at the transcriptional level. When phosphorylated CDK2, 7 and 9 were examined increasing SNS-032 concentrations decreased the levels of phosphorylated CDK7 and 9 detectable but not phosphorylated CDK2. Expression was quantitated using AIDA Image Analyser v4.19 (Fujifilm) and is shown relative to the tublin control and the untreated control sample. (d) Expression of CDK2, 7 and 9 at the mRNA level was also investigated using quantitative PCR following a 6 h exposure to SNS-032. The level of mRNA detected was compared with the level of expression of the housekeeping gene ABL and with untreated control samples. Expression of CDK 2 and 9 was found to be decreased relative to untreated samples on treatment with SNS-032 but CDK7 mRNA expression was not affected. The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML E Walsby et al SNS-032 shows strong synergy with Ara-C in primary AML cells
Given the putative mechanism of function of SNS-032, and the lack of strong correlation between SNS-032 and Ara-C, we next explored the potential for these agents to synergize with one another. The optimal molar ratio for the combination of these agents was determined experimentally using the MTS assay. To establish the most effective concentration range for each agent, dose-response curves were generated and LD 50 values (the concentration required to kill 50% of the cells) were calculated using non-linear (sigmoidal) regression analysis. In subsequent experiments cells were treated with serial dilutions of each drug individually and with both drugs simultaneously in a fixed ratio. Analysis of the combined drug effects was made using the median effect method. Briefly, this involved plotting the doseresponse curves for each drug and for multiple diluted fixedratio combinations and then calculating the combination index (CI). Both agents were used at therapeutically relevant concentrations in all of the in vitro assays that is, maximum concentrations were below the maximum tolerated/therapeutic dose. SNS-032 plasma concentrations of 0.3 mM have been achieved in B-cell malignancies in phase 1 trials 16 while plasma concentrations between 1.0 and 50 mM, depending on the dosing regime used, have been previously reported. 20 On the basis of an assessment of the CI values, the optimal molar ratio for SNS-032:Ara-C was 1:1.9. All 25 primary AML samples tested showed a very strong synergistic interaction between the two agents with a mean CI of 0.25 ± 0.23 ( Figure 5 ). Synergy was also seen in both the NB4 and HL-60 cell lines when SNS-032 and Ara-C were combined at the same ratio (mean CI of NB4 cells 0.56±0.08, mean CI of HL-60 cells 0.08±0.09).
Molecular determination of mechanisms of synergy
Given the strong synergistic interaction between SNS-032 and Ara-C, it seemed likely that their primary mechanisms of function were distinct from one another. We therefore, set out to investigate the effects of these agents both alone and in combination at the molecular level. In the first instance, we assessed the mRNA expression of CDK2, CDK7 and CDK9 following exposure to SNS-032, Ara-C and the combination thereof in the NB4 and HL-60 cell lines. CDK2 and CDK9 mRNA expression were significantly downregulated in response to SNS-032 alone and in combination with Ara-C. However, Ara-C alone had no significant effect on CDK2 or CDK9 transcription (Figures 6a and c) . In contrast, CDK7 mRNA expression was not significantly altered following treatment with SNS-032 or the combination but was increased by treatment with Ara-C alone (Figure 6b) . Taken together, these data suggest that Ara-C does not interfere with the mechanisms by which SNS-032 exerts its cytotoxic effects through inhibition of CDK2 and 9 at the mRNA level. However, this does not seem to provide a rationale for the synergy seen between the two agents.
We next focused our attention on genes that are transcriptionally regulated by CDK7 and CDK9 in particular we investigated the transcription of the antiapoptotic genes MCL1, XIAP and BCL2. Using quantitative PCR following 6 h of treatment of NB4 and HL-60 cells, we measured the level of mRNA expression of MCL1, XIAP and BCL2 in response to the agents both alone and in combination. MCL1 expression was variable when treated with SNS-032 (Figure 6d ), but we did not observe the large decreases in expression that other groups have reported in response to CDK inhibitors in CLL and osteosarcoma cells. 7, 8, 16, 21 However, SNS-032 treatment of the cell lines resulted in significant decreases in both XIAP (Figure 6e ; Po0.0001) and BCL2 (Figure 6f ; Po0.0001), which is consistent with previous reports of CDK inhibitors in other diseases. 7, 8, 16, [21] [22] [23] Importantly, treatment with Ara-C alone significantly increased the transcription of BCL2 and XIAP (P ¼ 0.0002 and P ¼ 0.0028, respectively). Both of these genes have been implicated in drug resistance mechanisms in AML [24] [25] [26] [27] and so their transcriptional activation may limit the apoptotic response to Ara-C. Remarkably, the combination of SNS-032 and Ara-C resulted in decreased MCL1 expression Figure 5 The existence of synergy between SNS-032 and Ara-C was determined using a ratio of 1 SNS-032 to 1.9 Ara-C and treating 25 primary AML samples to these two agents separately and in combination for 48 h. The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML E Walsby et al (P ¼ 0.021) and decreased expression of XIAP (Po0.0001) and BCL2 (P ¼ 0.0002), providing a rationale for at least one mechanism for the synergy seen with these agents. We hypothesize that SNS-032-mediated inhibition of antiapoptotic genes would increase the sensitivity of AML cells to the effects of Ara-C in the combination thereby inducing cytotoxic synergy.
Discussion
AML remains a difficult disease to treat and survival times remain disappointingly short. [28] [29] [30] CDKs have an essential role in cell proliferation and their potential as molecular targets for anti-cancer therapies has becoming increasingly recognised. 31 As the development of the pan CDK inhibitor flavopiridol more specific CDK inhibitors have been developed [32] [33] [34] with encouraging results. In this study, we present our findings on the CDK inhibitor SNS-032 in primary AML cells both alone and in combination with Ara-C.
SNS-032 resulted in in vitro cell killing, at a sub-micromolar level, in samples derived from 87 newly diagnosed AML patients. Additionally, we used the myeloid cell lines NB4 and HL-60 to demonstrate that SNS-032 results in apoptosis as evidenced by increased annexin V and PI staining and elevated levels of caspase-3 activation. Although these cell lines do not reflect the heterogeneity of the AML subgroups, they are informative about many aspects of the responses of AML cells to new agents. 35 Previously SNS-032 has been shown to have cell killing activity in glioblastoma 18 and CLL. 16 In the CLL study SNS-032 activity was found to be selective for CLL cells compared with non-malignant cells and its efficacy was not affected by patient characteristics, p53 status or fludarabine resistance making it potentially useful in refractory AML patients too.
In this study, we showed that SNS-032 modulates the effects of CDKs at both the transcriptional and post-translational levels. CDK2 and CDK9 were inhibited by SNS-032 at the transcriptional level while CDK7 was prevented from being activated through the inhibition of protein phosphorylation. These results are similar to those previously reported data in CLL cells. 16 Furthermore, we investigated the downstream effects of CDK7 and CDK9 inhibition on phosphorylation of RNA pol II at serine 5 and 2, respectively. We showed dephosphorylation of serine 2 at all the drug concentrations used and a concentrationdependent dephosphorylation at serine 5 using the same concentrations. Crucially, these results were recapitulated in primary AML cells demonstrating that these effects were not confined to the two cell lines used in this study.
Importantly, the combination of SNS-032 with Ara-C demonstrated a remarkable degree of cytotoxic synergy. CDK inhibitors, specifically flavopiridol, have previously been suggested to have the capacity to be enhancers of cytotoxic chemotherapy, potentially through CDK9 inhibition resulting in inhibition of RAD51, a DNA repair protein involved in homologous recombination. 17 The same study suggested that hematological malignancies might be more sensitive to cellcycle blockade and apoptosis induction than solid tumors. It is worthy of note here that the vast majority of primary AML cells show little evidence of cell-cycle activity in vitro so the principal cytotoxic effects of SNS-032 are likely to be caused by transcriptional repression rather than cell-cycle arrest in our in vitro assays. In this regard, the antiapoptotic genes BCL2 and XIAP were significantly downregulated by SNS-032 alone and in combination with Ara-C, under which conditions MCL1 expression was also inhibited. This pattern of inhibition of antiapoptotic genes has also been observed in response to flavopiridol, seliciclib and SNS-032 in CLL cells 7, 16 and in osteosarcoma cell lines. 8 Reduction of antiapoptotic proteins Figure 6 The molecular mechanism by which Ara-C and SNS-032 function in synergy was investigated at the mRNA level by quantitative PCR following 6-h treatment of NB4 an HL-60 cells. Expression levels of (a) CDK2, (b) CDK7 and (c) CDK9 showed that Ara-C in combination with SNS-032 reduced the expression of CDK2 and CDK9 but not CDK7. This suggests that Ara-C does not interfere with primary effects that SNS-032 exerts on these myeloid cell lines. Additionally the expression of antiapoptotic genes (d) MCL1, (e) XIAP and (f) BCL2 were analysed. All three genes were significantly inhibited by the combination of Ara-C and SNS-032 suggesting that suppression antiapoptotic genes may contribute to the high levels of synergy seen between these two agents.
The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML E Walsby et al in response to treatment with CDK inhibitors may be adequate to induce significant cell death in some instances. Furthermore, their inhibition may sensitize cancer cells to other apoptotic stimuli resulting from DNA damage. 7 Previous studies have shown that these elevated expression of these proteins can inhibit cytotoxic responses to chemotherapeutic agents like Ara-C. [36] [37] [38] In this regard, our data suggests that exposure to Ara-C increases the transcription of antiapoptotic genes and this may be important in the development of drug resistance to this agent. [38] [39] [40] In contrast, the combination of SNS-032 and Ara-C significantly suppressed the transcription of these same antiapoptotic genes. Undoubtedly, the mechanisms of synergy between these agents are complex. However, the level of suppression of antiapoptotic genes observed with the combination may be sufficient to sensitise AML cells to the DNA damaging effects of Ara-C and thereby provide a rationale for the cytotoxic synergy observed.
SNS-032 was selected for development based on its favorable characteristics including low protein binding in human serum 41 compared with the high degree of protein binding (92-95%) seen with flavopiridol. 42 A phase I study of SNS-032 in solid tumors including lung cancer, breast cancer and melanoma showed that this agent was well tolerated and oral administration may be feasible. 43 In addition, a phase I study in advanced B-cell lymphoid malignancy is ongoing. 17 In this study, we showed that SNS-032 is effective in primary AML cells in vitro as a single agent and also demonstrated remarkable synergy with Ara-C. Importantly, the concentrations of SNS-032 used in these studies were lower than the maximum tolerated dose observed in the clinical trials to date. Taken together, our data indicate that SNS-032 should be considered for early-phase clinical trials in AML, as it seems to have utility both as a single agent and in combination with Ara-C.
